Lori J. Wirth, MD

A panelist discusses how the integration of immunotherapy into recurrent/metastatic (R/M) nasopharyngeal carcinoma (NPC) treatment requires careful patient monitoring for immune-related adverse events, strategic sequencing with other modalities, consideration of biomarker-guided approaches, and awareness of emerging combination strategies that may further improve outcomes, while ongoing research into novel immunotherapeutic agents, maintenance strategies, and treatment de-escalation protocols aims to optimize efficacy while minimizing toxicity in the evolving landscape of NPC management.

A panelist discusses how immunotherapy combined with chemotherapy has revolutionized recurrent/metastatic (R/M) nasopharyngeal carcinoma (NPC) treatment through improved survival outcomes demonstrated in landmark trials such as JUPITER-02 with toripalimab and KEYNOTE-590 with pembrolizumab, emphasizing that although most patients benefit regardless of PD-L1 status or Epstein-Barr virus positivity, clinicians must carefully consider patient-specific factors, such as performance status and comorbidities, alongside the management of unique immune-related adverse events through early recognition, established treatment algorithms, and multidisciplinary collaboration to optimize outcomes in this evolving treatment landscape.

A panelist discusses how treatment strategies for recurrent nasopharyngeal carcinoma (NPC) have evolved, with the updated NCCN guidelines now recommending toripalimab plus gemcitabine/cisplatin as category 1 first-line therapy for recurrent/metastatic (R/M) disease based on the JUPITER-02 trial results showing significantly improved 4-year overall survival (OS) rates of 48% vs 27.7% with chemotherapy alone, while emphasizing that treatment decisions should consider patient-specific factors, such as Epstein-Barr virus status, prior treatments, and comorbidities, alongside nonpatient factors, including drug accessibility, need for rapid response, and capacity to manage immune-related adverse events.

A panelist discusses how a 48-year-old man with recurrent nasopharyngeal carcinoma (NPC) presents with nasal congestion, epistaxis, neck swelling, and unilateral hearing issues, highlighting the importance of recognizing these symptoms in patients with a family history of NPC.

A panelist discusses how nasopharyngeal carcinoma (NPC) differs from other head and neck malignancies through its distinct geographical distribution, Epstein-Barr virus association, unique genetic profile, and characteristic clinical presentation, including early lymph node involvement.

Lori J. Wirth, MD, offers advice to oncologists using lenvatinib when treating patients with differentiated thyroid cancer.

Lori J. Wirth, MD, discusses some of the unmet needs that exist in the thyroid cancer space following the FDA approval for lenvatinib for radioactive iodine-refractory differentiated thyroid cancer.

Lori J. Wirth, MD, discusses some of the emerging trends and developments that are on the horizon in the thyroid cancer space.

Lori J. Wirth, MD, discusses the role of lenvatinib following its approval from the FDA for the treatment of patients with radioactive iodine-refractory differentiated thyroid cancer.

Lori J. Wirth, MD, discusses safety data from the phase 3 SELECT trial which evaluated lenvatinib in radioactive iodine-refractory differentiated thyroid cancer.

Lori J. Wirth, MD, discusses the background and design of the phase 3 SELECT trial of lenvatinib vs placebo for the treatment of patients with radioactive iodine-refractory differentiated thyroid cancer.

Lori J. Wirth, MD, discusses some of the ongoing clinical trials investigating innovative therapies or combinations for the treatment of patients with thyroid cancer.

Lori J. Wirth, MD, discusses the outcomes of treatment with larotrectinib for patients with NTRK fusion–positive advanced thyroid cancer.

Lori J. Wirth, MD, discusses imaging techniques, biomarker identification, and promising treatments on the horizon in the thyroid cancer space.

Lori J. Wirth, MD, provides an overview on the latest advancements in diagnosis of thyroid cancer.

Lori Wirth, MD, discusses second-line treatment in relation to the patient case, and concludes the discussion with a look at emerging treatment options and the future of treating advanced RAI-refractory DTC.

An expert on thyroid cancer provides insights on treating patients with advanced RAI-refractory DTC who harbor BRAFV600E mutations.

Lori Wirth, MD, discusses molecular testing practices for patients with advanced RAI-refractory differentiated thyroid cancer.

A medical oncologist reviews real-world data on older patients with RAI-refractory DTC and provides her thoughts on treating this patient population.

An overview of the standard of care treatment for patients with advanced radioiodine-refractory differentiated thyroid cancer.

Lori Wirth, MD, discusses the safety profiles of sorafenib and lenvatinib and provides clinical insights on managing or mitigating adverse effects.

A medical oncologist provides a comprehensive overview of the current treatment options for patients with advanced RAI-refractory DTC and reviews clinical trial data on sorafenib and lenvatinib.

A leading expert on head and neck oncology provides her initial impressions on the case of a 64-year-old woman with differentiated thyroid cancer.

Lori Wirth, MD, a medical oncologist, reviews the case of a 64-year-old woman with differentiated thyroid cancer (DTC).

Dr Lori Wirth highlights remaining unmet needs and challenges in the treatment of advanced RAI-R-DTC.

Lori Wirth, MD, explains why the importance of molecular alterations in her treatment decision-making for a patient with advanced RAI-R-DTC, and the other factors she considers for an appropriate treatment.

Lori Wirth, MD, explains what regimen is considered to be the standard-of-care treatment for patients with advanced RAI-R-DTC.

Dr Lori Wirth discusses the design and data of two key clinical trials that led to the approval of the current treatment options for patients with advanced RAI-R-DTC.

Dr Lori Wirth details the common molecular alterations seen in patients with advanced RAO-R-DTC and which testing platforms she recommends.